FDA approves Celgene's Thalomid for myeloma

Celgene has received an approvable letter from the FDA to expand the use of Thalomid for multiple myeloma. The letter typically indicates that a drug developer will need to submit additional information before final approval is given. Thalomid is approved for leprosy but is often used off-label for cancer.

- read this AP report for more